



UNIVERSITAT<sup>DE</sup>  
BARCELONA

## Caracterización de la estadificación molecular en carcinoma de colon. Correlación clínico-histológica

Iban Aldecoa Ansórrregui



Aquesta tesi doctoral està subjecta a la llicència **Reconeixement 3.0. Espanya de Creative Commons.**

Esta tesis doctoral está sujeta a la licencia **Reconocimiento 3.0. España de Creative Commons.**

This doctoral thesis is licensed under the **Creative Commons Attribution 3.0. Spain License.**

# BIBLIOGRAFÍA

---



1. Singh-Ranger, G. The American Joint Committee on Cancer staging (AJCC) Atlas, by Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP. *Int. Semin. Surg. Oncol.* **3**, 34 (2006).
2. Stewart, S. L., Wike, J. M., Kato, I., Lewis, D. R. & Michaud, F. A population-based study of colorectal cancer histology in the United States, 1998–2001. *Cancer* **107**, 1128–1141 (2006).
3. Tang, L. H. *et al.* Protocol for the Examination of Specimens from Patients With Primary Carcinoma of the Colon and Rectum. College of American Pathologists. (2016).
4. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. *CA. Cancer J. Clin.* **66**, 7–30 (2016).
5. Quintero, E. *et al.* Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. *N. Engl. J. Med.* **366**, 697–706 (2012).
6. AECC. Incidencia del cáncer de colon. *Asociación Española contra el Cáncer* (2016). Available at: <https://www.aecc.es/SobreElCancer/CancerPorLocalizacion/cancerdecolon/Paginas/incidencia.aspx>. (Accessed: 12th October 2016)
7. Ferlay, J. *et al.* Las Cifras del Cáncer en España 2014. *Soc. Española Oncol. Médica* (2014).
8. Castells, A., Castellví-Bel, S. & Balaguer, F. Concepts in familial colorectal cancer: where do we stand and what is the future? *Gastroenterology* **137**, 404–9 (2009).
9. Sobin LH, Gospodarowicz MK, Witte C. *UICC: TNM Classification of Malignant Tumours*. (Wiley-Blackwell, 2009).
10. Trejo, D. S. El cribado del cáncer de colon en España : Situación 2006-2014. *Red de Programas de Cribado de Cáncer* (2014).
11. AECC. Programa de cribado de cáncer de colon implantado al 100% en el País Vasco. *Vitoria-Gasteiz* Available at: <https://www.aecc.es/Comunicacion/Noticias/Paginas/Programadecribadodecolonimplantadoal100enelPaísVasco.aspx>.
12. Levin, B. *et al.* Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA. Cancer J. Clin.* **58**, 130–160 (2008).
13. Silvia, C. *et al.* Barreras en la implantación del cribado del cáncer de colon en España. (Alianza para la Prevención del Cáncer de Colon en España. Madrid, 2011, 2011).
14. Wolff, W. I. Colonoscopy: history and development. *Am. J. Gastroenterol.* **84**, 1017–25 (1989).
15. Washington, M. K. *et al.* Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. *Arch. Pathol. Lab. Med.* **133**, 1539–1551 (2009).
16. Williams, J. G. *et al.* Management of the malignant colorectal polyp: ACPGIBI position statement. *Color. Dis.* **15**, 1–38 (2013).
17. Bertelson, N. L. *et al.* Colectomy for Endoscopically Unresectable Polyps. *Dis. Colon Rectum* **55**, 1111–1116 (2012).
18. Bujanda, L., Cosme, A., Gil, I. & Arenas-Mirave, J. I. Malignant colorectal polyps. *World J. Gastroenterol.* **16**, 3103–3111 (2010).
19. Ellis, K. K. & Fennerty, M. B. Marking and identifying colon lesions. Tattoos, clips, and radiology in imaging the colon. *Gastrointest. Endosc. Clin. N. Am.* **7**, 401–11 (1997).
20. Sauntry, J. P. & Knudtson, K. P. A technique for marking the mucosa of the gastrointestinal tract after polypectomy. *Cancer* **11**, 607–10
21. Knoernschild, H. E. The use of a tattooing instrument for marking colonic mucosa. *Am. J. Surg.* **103**, 83–5 (1962).
22. Ponsky, J. L. & King, J. F. Endoscopic marking of colonic lesions. *Gastrointest. Endosc.* **22**, 42–3 (1975).
23. Hammond, D. C. *et al.* Endoscopic tattooing of the colon. An experimental study. *Am. Surg.* **55**, 457–61 (1989).
24. Askin, M. P., Wayne, J. D., Fiedler, L. & Harpaz, N. Tattoo of colonic neoplasms in 113 patients with a new sterile carbon compound. *Gastrointest. Endosc.* **56**, 339–42 (2002).
25. Nizam, R., Siddiqi, N., Landas, S. K., Kaplan, D. S. & Holtzapple, P. G. Colonic tattooing with India ink: benefits, risks, and alternatives. *Am. J. Gastroenterol.* **91**, 1804–8 (1996).
26. Kethu, S. R. *et al.* Endoscopic tattooing. *Gastrointest. Endosc.* **72**, 681–5 (2010).
27. Trakarnsanga, A. Endoscopic tattooing of colorectal lesions: Is it a risk-free procedure? *World J. Gastrointest. Endosc.* **3**, 256 (2011).
28. Salomon, P., Berner, J. S. & Wayne, J. D. Endoscopic India ink injection: a method for preparation, sterilization, and administration. *Gastrointest. Endosc.* **39**, 803–5
29. Ginsberg, G. G. *et al.* The argon plasma coagulator: February 2002. *Gastrointest. Endosc.* **55**, 807–10 (2002).
30. Botoman, V. A., Pietro, M. & Thirlby, R. C.

- Localization of colonic lesions with endoscopic tattoo. *Dis. Colon Rectum* **37**, 775–6 (1994).
31. Hornig, D., Kühn, H., Stadelmann, O. & Bötticher, R. Phlegmonous gastritis after Indian ink marking. *Endoscopy* **15**, 266–9 (1983).
  32. Coman, E. *et al.* Fat necrosis and inflammatory pseudotumor due to endoscopic tattooing of the colon with india ink. *Gastrointest. Endosc.* **37**, 65–8
  33. Dell'Abate, P. *et al.* Endoscopic preoperative colonic tattooing: a clinical and surgical complication. *Endoscopy* **31**, 271–3 (1999).
  34. Park, S. I., Genta, R. S., Romeo, D. P. & Weesner, R. E. Colonic abscess and focal peritonitis secondary to india ink tattooing of the colon. *Gastrointest. Endosc.* **37**, 68–71
  35. McArthur, C. S., Roayaie, S. & Wayne, J. D. Safety of preoperation endoscopic tattoo with india ink for identification of colonic lesions. *Surg. Endosc.* **13**, 397–400 (1999).
  36. Cahill, R. A., Lindsey, I. & Cunningham, C. Sentinel node mapping by colonic tattooing. *Surg. Endosc.* **24**, 2365–6 (2010).
  37. Dawson, K., Wiebusch, A. & Thirlby, R. C. Preoperative tattooing and improved lymph node retrieval rates from colectomy specimens in patients with colorectal cancers. *Arch. Surg.* **145**, 826–830 (2010).
  38. Bartels, S. A. L., van der Zaag, E. S., Dekker, E., Buskens, C. J. & Bemelman, W. A. The effect of colonoscopic tattooing on lymph node retrieval and sentinel lymph node mapping. *Gastrointest. Endosc.* **76**, 793–800 (2012).
  39. Kang, J. *et al.* Effect of preoperative colonoscopic tattooing on lymph node harvest in T1 colorectal cancer. *Int. J. Colorectal Dis.* **30**, 1349–1355 (2015).
  40. Feo, C. V. *et al.* Preoperative endoscopic tattooing to mark the tumour site does not improve lymph node retrieval in colorectal cancer: a retrospective cohort study. *J. Negat. Results Biomed.* **14**, 9 (2015).
  41. Spatz, H. *et al.* Sentinel lymph node mapping as a side-effect of colonoscopic tattooing. *Surg. Endosc.* **24**, 589–93 (2009).
  42. Viehl, C. T. *et al.* Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients. *World J. Surg.* **30**, 453–456 (2006).
  43. Dunaway, M. T., Webb, W. R. & Rodning, C. B. Intraluminal measurement of distance in the colorectal region employing rigid and flexible endoscopes. *Surg. Endosc.* **2**, 81–3 (1988).
  44. Frager, D. H., Frager, J. D., Wolf, E. L. & Beneventano, T. C. Problems in the colonoscopic localization of tumors: continued value of the barium enema. *Gastrointest. Radiol.* **12**, 343–6 (1987).
  45. Cho, Y. B. *et al.* Tumor localization for laparoscopic colorectal surgery. *World J. Surg.* **31**, 1491–1495 (2007).
  46. Poulard, J. B., Shatz, B. & Kodner, I. Preoperative tattooing of polypectomy site. *Endoscopy* **17**, 84–5 (1985).
  47. Zmora, O. *et al.* Intraoperative endoscopy in laparoscopic colectomy. *Surg. Endosc.* **16**, 808–11 (2002).
  48. Montorsi, M. *et al.* Original technique for small colorectal tumor localization during laparoscopic surgery. *Dis. Colon Rectum* **42**, 819–22 (1999).
  49. Desch, C. E. *et al.* Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. *J. Clin. Oncol.* **23**, 8512–9 (2005).
  50. Meyerhardt, J. A. *et al.* Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American society of clinical oncology clinical practice guideline endorsement. *J. Clin. Oncol.* **31**, 4465–4470 (2013).
  51. Hammarström, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. *Semin. Cancer Biol.* **9**, 67–81 (1999).
  52. Nicholson, B. D. *et al.* Blood Measurement of Carcinoembryonic Antigen Level for Detecting Recurrence of Colorectal Cancer. *JAMA* **316**, 1310 (2016).
  53. Gold, B., Cankovic, M., Furtado, L. V., Meier, F. & Gocke, C. D. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility?: A report of the association for molecular pathology. *J. Mol. Diagnostics* **17**, 209–224 (2015).
  54. Pohl, M. & Schmiegel, W. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and beyond Targeted Therapies in Colon Cancer Today and Tomorrow. *Dig. Dis.* **34**, 574–579 (2016).
  55. Ignatiadis, M., Lee, M. & Jeffrey, S. S. Circulating tumor cells and circulating tumor DNA: Challenges and opportunities on the path to clinical utility. *Clin. Cancer Res.* **21**, 4786–4800 (2015).
  56. Abdallah, E. A. *et al.* Thymidylate synthase

- expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. *Int. J. cancer* **137**, 1397–405 (2015).
57. Yokobori, T. *et al.* Platin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. *Cancer Res.* **73**, 2059–69 (2013).
  58. Diaz, L. A. *et al.* The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* **486**, 537–40 (2012).
  59. Hsieh, J.-S. *et al.* APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. *Am. Surg.* **71**, 336–43 (2005).
  60. Wang, J.-Y. *et al.* Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. *World J. Surg.* **28**, 721–6 (2004).
  61. NCCN. *Colon Cancer. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 2.2016, 02/08/2016.* (2016).
  62. NCCN. *New NCCN Guidelines Include Evidence Blocks to Illustrate Value in Breast, Colon, Kidney, and Rectal Cancers. J. Natl. Compr. Canc. Netw.* **14**, xxxiv–xxxv (2016).
  63. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N. Engl. J. Med.* **350**, 2050–9 (2004).
  64. Lacy, A. M. *et al.* Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. *Lancet* **359**, 2224–9 (2002).
  65. Wishner, J. D. *et al.* Laparoscopic-assisted colectomy. The learning curve. *Surg. Endosc.* **9**, 1179–83 (1995).
  66. Ota, D. M., Nelson, H. & Weeks, J. C. Controversies regarding laparoscopic colectomy for malignant diseases. *Curr. Opin. Gen. Surg.* 208–13 (1994).
  67. Abdalla, E. K. *et al.* Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann. Surg.* **239**, 818–25–7 (2004).
  68. Chamsangavej, C. *et al.* Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. *Ann. Surg. Oncol.* **13**, 1261–8 (2006).
  69. Fong, Y. *et al.* Liver resection for colorectal metastases. *J. Clin. Oncol.* **15**, 938–46 (1997).
  70. Covey, A. M. *et al.* Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. *Ann. Surg.* **247**, 451–5 (2008).
  71. Rena, O. *et al.* Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. *Eur. J. Cardiothorac. Surg.* **21**, 906–12 (2002).
  72. Irshad, K., Ahmad, F., Morin, J. E. & Mulder, D. S. Pulmonary metastases from colorectal cancer: 25 years of experience. *Can. J. Surg.* **44**, 217–21 (2001).
  73. Ambiru, S. *et al.* Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. *Cancer* **82**, 274–8 (1998).
  74. André, T. *et al.* Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J. Clin. Oncol.* **27**, 3109–16 (2009).
  75. André, T. *et al.* Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. *N. Engl. J. Med.* **350**, 2343–2351 (2004).
  76. Kuebler, J. P. *et al.* Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. *J. Clin. Oncol.* **25**, 2198–204 (2007).
  77. Twelves, C. *et al.* Capecitabine as adjuvant treatment for stage III colon cancer. *N. Engl. J. Med.* **352**, 2696–704 (2005).
  78. Benson, A. B. *et al.* American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J. Clin. Oncol.* **22**, 3408–3419 (2004).
  79. Benson, A. B. *et al.* Colon cancer, version 3.2014. *J. Natl. Compr. Canc. Netw.* **12**, 1028–1059 (2014).
  80. Jiang, N., Deng, J.-Y., Ding, X.-W., Liu, Y. & Liang, H. Tumor Volume as a Prognostic Factor was Superior to the Seventh Edition of the pT Classification in Resectable Gastric Cancer. *Eur. J. Surg. Oncol.* (2014). doi:10.1016/j.ejso.2014.11.045
  81. Toh, E.-W., Brown, P., Morris, E., Botterill, I. & Quirke, P. Area of submucosal invasion and width of invasion predicts lymph node metastasis in pT1 colorectal cancers. *Dis. Colon Rectum* **58**, 393–400 (2015).
  82. Compton CC. in (ed. Gospodarowicz MK, O’Sullivan B, S. L.) 133–137
  83. Kang, H., O’Connell, J. B., Maggard, M. A., Sack, J. & Ko, C. Y. A 10-year outcomes evaluation of mucinous and signet-ring cell

- carcinoma of the colon and rectum. *Dis. Colon Rectum* **48**, 1161–8 (2005).
84. Bernick, P. E. *et al.* Neuroendocrine carcinomas of the colon and rectum. *Dis. Colon Rectum* **47**, 163–9 (2004).
  85. Prall, F. Tumour budding in colorectal carcinoma. *Histopathology* **50**, 151–162 (2007).
  86. Koelzer, V. H., Zlobec, I. & Lugli, A. Tumor budding in colorectal cancer-ready for diagnostic practice? *Hum. Pathol.* **47**, 4–19 (2016).
  87. Lim, S.-B. *et al.* Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. *Dis. Colon Rectum* **53**, 377–84 (2010).
  88. Santos, C. *et al.* Clinicopathological risk factors of Stage II colon cancer: results of a prospective study. *Colorectal Dis.* **15**, 414–22 (2013).
  89. Liebig, C. *et al.* Perineural invasion is an independent predictor of outcome in colorectal cancer. *J. Clin. Oncol.* **27**, 5131–7 (2009).
  90. Ueno, H. *et al.* Characterization of perineural invasion as a component of colorectal cancer staging. *Am. J. Surg. Pathol.* **37**, 1542–9 (2013).
  91. Gomez, D. *et al.* Critical review of the prognostic significance of pathological variables in patients undergoing resection for colorectal liver metastases. *HPB (Oxford)*. **16**, 836–44 (2014).
  92. Betge, J. *et al.* Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. *Cancer* **118**, 628–38 (2012).
  93. Kirsch, R. *et al.* Venous invasion in colorectal cancer: impact of an elastin stain on detection and interobserver agreement among gastrointestinal and nongastrointestinal pathologists. *Am. J. Surg. Pathol.* **37**, 200–10 (2013).
  94. Guinney, J. *et al.* The consensus molecular subtypes of colorectal cancer. *Nat. Med.* **21**, 1350–1356 (2015).
  95. Turnpenny, P. D. & Ellard, S. *Emery's elements of medical genetics.* (Elsevier/Churchill Livingstone, 2012).
  96. Musulén, E., Sanz, C., Muñoz-Mármol, A. M. & Ariza, A. Mismatch repair protein immunohistochemistry: A useful population screening strategy for Lynch syndrome. *Hum. Pathol.* **45**, 1388–1396 (2014).
  97. Rahner, N. *et al.* Clinical utility gene card for : Lynch syndrome. *Eur. J. Hum. Genet.* **21**, 1–3 (2012).
  98. Lynch, H. *et al.* Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin. Genet.* **76**, 1–18 (2009).
  99. Bartley, A. N. *et al.* *Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Colon and Rectum.* (2014).
  100. Moreira, L. *et al.* Identification of Lynch syndrome among patients with colorectal cancer. *Jama* **308**, 1555–65 (2012).
  101. Boland, C. R. *et al.* A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer. *Cancer Res.* **58**, (1998).
  102. Buecher, B. *et al.* Role of microsatellite instability in the management of colorectal cancers. *Dig. Liver Dis.* **45**, 441–9 (2013).
  103. Lièvre, A. *et al.* KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res.* **66**, 3992–5 (2006).
  104. Amado, R. G. *et al.* Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J. Clin. Oncol.* **26**, 1626–34 (2008).
  105. Allegra, C. J. *et al.* American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J. Clin. Oncol.* **27**, 2091–6 (2009).
  106. Douillard, J.-Y. *et al.* Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N. Engl. J. Med.* **369**, 1023–34 (2013).
  107. Dalerba, P. *et al.* CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. *N. Engl. J. Med.* **374**, 211–222 (2016).
  108. Rahbari, N. N. *et al.* Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: A systematic review and meta-analysis. *J. Clin. Oncol.* **30**, 60–70 (2012).
  109. Hyslop, T. & Waldman, S. a. Molecular staging of node negative patients with colorectal cancer. *J. Cancer* **4**, 193–199 (2013).
  110. Compton, C. C. Optimal pathologic staging: defining stage II disease. *Clin. Cancer Res.* **13**, 6862s–70s (2007).
  111. Iddings, D., Ahmad, A., Elashoff, D. &

- Bilchik, A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. *Ann. Surg. Oncol.* **13**, 1386–1392 (2006).
112. Sloothak, D. A. M. *et al.* The prognostic value of micrometastases and isolated tumour cells in histologically negative lymph nodes of patients with colorectal cancer: a systematic review and meta-analysis. *Eur. J. Surg. Oncol.* **40**, 263–269 (2014).
  113. Güller, U. *et al.* Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): a new road to better staging? *Cancer* **118**, 6039–6045 (2012).
  114. Yamamoto, H. *et al.* OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: results from a multicenter clinical performance study in Japan. *Ann. Surg. Oncol.* **18**, 1891–1898 (2011).
  115. Vogelaar, F. J. *et al.* The diagnostic value of one-step nucleic acid amplification (OSNA) for sentinel lymph nodes in colon cancer patients. *Ann. Surg. Oncol.* **21**, 3924–3930 (2014).
  116. Croner, R. S. *et al.* Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study. *Br. J. Cancer* **110**, 2544–2550 (2014).
  117. Croner, R. S. *et al.* One step nucleic acid amplification (OSNA) - a new method for lymph node staging in colorectal carcinomas. *J. Transl. Med.* **8**, 83 (2010).
  118. Yamamoto, N. *et al.* An optimal mRNA marker for OSNA (One-step nucleic acid amplification) based lymph node metastasis detection in colorectal cancer patients. *Jpn. J. Clin. Oncol.* **43**, 264–270 (2013).
  119. Wanebo, H. J. *et al.* Meeting the biologic challenge of colorectal metastases. *Clin. Exp. Metastasis* **29**, 821–839 (2012).
  120. Belly, R. T. *et al.* Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. *Clin. Colorectal Cancer* **1**, 110–6 (2001).
  121. Cagir, B. *et al.* Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. *Ann. Intern. Med.* **131**, 805–12 (1999).
  122. Haince, J.-F. *et al.* Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. *J. Clin. Pathol.* **63**, 530–7 (2010).
  123. Koyanagi, K. *et al.* Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. *Clin. Cancer Res.* **14**, 7391–6 (2008).
  124. Liefers, G. J. *et al.* Micrometastases and survival in stage II colorectal cancer. *N. Engl. J. Med.* **339**, 223–8 (1998).
  125. Merrie, A. E. H. *et al.* Prognostic significance of occult metastases in colon cancer. *Dis. Colon Rectum* **46**, 221–31 (2003).
  126. Noura, S. *et al.* Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. *J. Clin. Oncol.* **20**, 4232–41 (2002).
  127. Rosenberg, R. *et al.* Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. *J. Clin. Oncol.* **20**, 1049–1055 (2002).
  128. Waldman, S. A. *et al.* Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. *JAMA* **301**, 745–52 (2009).
  129. Yamamoto, H. *et al.* OSNA-Assisted Molecular Staging in Colorectal Cancer: A Prospective Multicenter Trial in Japan. *Ann. Surg. Oncol.* 1–6 (2015). doi:10.1245/s10434-015-4880-x
  130. Lips, D. J. *et al.* The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute<sup>+</sup> Study. *BMC Surg.* **11**, 11 (2011).
  131. Tsujimoto, M. *et al.* One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. *Clin. Cancer Res.* **13**, 4807–4816 (2007).
  132. Visser, M. *et al.* Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. *Int. J. Cancer* **122**, 2562–2567 (2008).
  133. Peg, V. *et al.* Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. *Breast Cancer Res. Treat.* **139**, 87–93 (2013).
  134. Cserni, G. Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification. *J. Clin. Pathol.* **65**, 193–199 (2012).



135. Tamaki, Y. *et al.* Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. *Clin. Cancer Res.* **15**, 2879–2884 (2009).
136. Mori, Y., Nagamine, K., Tomita, N. & Notomi, T. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. *Biochem. Biophys. Res. Commun.* **289**, 150–4 (2001).
137. Osako, T. *et al.* Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: A comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. *Cancer* **117**, 4365–4374 (2011).
138. Schem, C. *et al.* One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. *Virchows Arch.* **454**, 203–210 (2009).
139. Tamaki, Y. One-step nucleic acid amplification assay (OSNA) for sentinel lymph node biopsy. *Breast Cancer* **22**, 230–4 (2015).
140. Rubio, I. T. *et al.* Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients. *Breast Cancer Res. Treat.* **147**, 371–380 (2014).
141. Castellano, I. *et al.* Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastases. *Ann. Surg.* **255**, 334–42 (2012).
142. Godey, F. *et al.* Sentinel lymph node analysis in breast cancer: Contribution of one-step nucleic acid amplification (OSNA). *Breast Cancer Res. Treat.* **131**, 509–516 (2012).
143. Espinosa-Bravo, M. *et al.* Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. *Eur. J. Surg. Oncol.* **39**, 766–773 (2013).
144. Tamaki, Y. *et al.* Routine clinical use of the one-step nucleic acid amplification assay for detection of sentinel lymph node metastases in breast cancer patients: Results of a multicenter study in Japan. *Cancer* **118**, 3477–3483 (2012).
145. Khaddage, A. *et al.* Implementation of molecular intra-operative assessment of sentinel lymph node in breast cancer. *Anticancer Res.* **31**, 585–90 (2011).
146. Yamamoto, H. *et al.* Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. *Clin. Cancer Res.* **i**, (2016).
147. Cabanas, R. M. An approach for the treatment of penile carcinoma. *Cancer* **39**, 456–66 (1977).
148. Giuliano, A. E., Kirgan, D. M., Guenther, J. M. & Morton, D. L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. *Ann. Surg.* **220**, 391-8-401 (1994).
149. Bilchik, A. J. *et al.* Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. *Cancer J. Sci. Am.* **4**, 351–8
150. Morton, D. L. *et al.* Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch. Surg.* **127**, 392–9 (1992).
151. Huynh, K. T. & Bilchik, A. J. Sentinel lymph node biopsy and nodal ultrastaging in colorectal cancer. *Cancer J.* **21**, 11–16 (2015).
152. Zaag, E. S. *et al.* Systematic Review of Sentinel Lymph Node Mapping Procedure in Colorectal Cancer. *Ann. Surg. Oncol.* **19**, 3449–3459 (2012).
153. Van Cutsem, E. & Oliveira, J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. *Ann. Oncol.* **20 Suppl 4**, 49–50 (2009).
154. American Cancer Society. Cancer Facts & Figures 2015. (2015).
155. Zavoral, M. *et al.* Colorectal cancer screening: 20 years of development and recent progress. *World J. Gastroenterol.* **20**, 3825–34 (2014).
156. Winawer, S. J. The history of colorectal cancer screening: a personal perspective. *Dig. Dis. Sci.* **60**, 596–608 (2015).
157. Kubisch, C. H., Crispin, A., Mansmann, U., Göke, B. & Kolligs, F. T. Screening for Colorectal Cancer is Associated with Lower Disease Stage: A Population-Based Study. *Clin. Gastroenterol. Hepatol.* (2016). doi:10.1016/j.cgh.2016.04.008
158. Laubert, T. *et al.* Metachronous metastasis-and survival-analysis show prognostic importance of lymphadenectomy for colon carcinomas. *BMC Gastroenterol.* **12**, 24 (2012).
159. Merkel, S. *et al.* High-risk groups of patients with Stage II colon carcinoma. *Cancer* **92**, 1435–1443 (2001).
160. Chang, G. J., Rodriguez-Bigas, M. A., Skibber, J. M. & Moyer, V. A. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. *J. Natl. Cancer Inst.*

- 99, 433–441 (2007).
161. O'Connor, E. S. *et al.* Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features. *J. Clin. Oncol.* **29**, 3381–3388 (2011).
  162. Quah, H.-M. *et al.* Identification of patients with high-risk stage II colon cancer for adjuvant therapy. *Dis. Colon Rectum* **51**, 503–507 (2008).
  163. Weitz, J. *et al.* Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. *Clin. Cancer Res.* **5**, 1830–1836 (1999).
  164. Klein, C. A. Parallel progression of primary tumours and metastases. *Nat. Rev. Cancer* **9**, 302–312 (2009).
  165. Nicastrì, D. G., Doucette, J. T., Godfrey, T. E. & Hughes, S. J. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. *J. Mol. Diagn.* **9**, 563–571 (2007).
  166. Aldecoa, I. *et al.* Molecularly determined total tumour load in lymph nodes of stage I-II colon cancer patients correlates with high-risk factors. A multicentre prospective study. *Virchows Arch.* (2016). doi:10.1007/s00428-016-1990-1
  167. Goldstein, N. S. Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. *Am. J. Surg. Pathol.* **26**, 179–189 (2002).
  168. Swanson, R. S., Compton, C. C., Stewart, A. K. & Bland, K. I. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. *Ann. Surg. Oncol.* **10**, 65–71 (2003).
  169. Hyslop, T., Weinberg, D. S., Schulz, S., Barkun, A. & Waldman, S. A. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. *J. Surg. Oncol.* **106**, 24–30 (2012).
  170. Soni, M. *et al.* Comparison of nodal positivity between SLNM vs conventional surgery in colon cancer patients with <math>\leq 12</math> and Am. J. Surg. **202**, 207–213 (2011).
  171. Sirop, S. *et al.* Detection and prognostic impact of micrometastasis in colorectal cancer. *J. Surg. Oncol.* **103**, 534–537 (2011).
  172. Gunderson, L. L., Jessup, J. M., Sargent, D. J., Greene, F. L. & Stewart, A. K. Revised TN categorization for colon cancer based on national survival outcomes data. *J. Clin. Oncol.* **28**, 264–271 (2010).
  173. Aldecoa, I. *et al.* Endoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden. *Surg. Endosc. Other Interv. Tech.* (2016). doi:10.1007/s00464-016-5026-3
  174. Mead, R., Duku, M., Bhandari, P. & Cree, I. A. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. *Br. J. Cancer* **105**, 239–45 (2011).
  175. Bettegowda, C. *et al.* Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci. Transl. Med.* **6**, 224ra24 (2014).
  176. Jeffers, M. D. *et al.* The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. *J. Pathol.* **172**, 183–187 (1994).
  177. Hanahan, D. & Weinberg, R. a. Hallmarks of cancer: The next generation. *Cell* **144**, 646–674 (2011).
  178. Chen, S. L. & Bilchik, A. J. More Extensive Nodal Dissection Improves Survival for Stages I to III of Colon Cancer. *Trans. ... Meet. Am. Surg. Assoc.* **124**, 267–275 (2006).
  179. Kelder, W. *et al.* Impact of the number of histologically examined lymph nodes on prognosis in colon cancer: a population-based study in the Netherlands. *Dis. Colon Rectum* **52**, 260–7 (2009).
  180. Johnson, P. M., Malatjalian, D. & Porter, G. A. Adequacy of nodal harvest in colorectal cancer: a consecutive cohort study. *J. Gastrointest. Surg.* **6**, 883–88-90
  181. Yeung, J. M. C., Maxwell-Armstrong, C. & Acheson, A. G. Colonic tattooing in laparoscopic surgery - making the mark? *Colorectal Dis.* **11**, 527–30 (2009).
  182. Beretvas, R. I. & Ponsky, J. Endoscopic marking: an adjunct to laparoscopic gastrointestinal surgery. *Surg. Endosc.* **15**, 1202–3 (2001).
  183. Dhar, D. K. *et al.* Metastatic lymph node size and colorectal cancer prognosis. *J. Am. Coll. Surg.* **200**, 20–28 (2005).
  184. Märkl, B. *et al.* The clinical significance of lymph node size in colon cancer. *Mod. Pathol.* **25**, 1413–1422 (2012).
  185. Lester, S. C., Bose, S., Chen, Y., Connolly, J. L. & Al, E. Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast. *Coll. Am. Pathol.* (2016).

